Contribution of endogenous glycine site NMDA agonists to excitotoxic retinal damage in vivo by Hama, Yasuhiro et al.
熊本大学学術リポジトリ
Kumamoto University Repository System
Title Contribution of endogenous glycine site NMDA
agonists to excitotoxic retinal damage in vivo
Author(s)Hama, Yasuhiro; Katsuki, Hiroshi; Tochikawa,
Yoshinaga; Suminaka, Chihiro; Kume, Toshiaki;
Akaike, Akinori
CitationNeuroscience Research, 56(3): 279-285
Issue date2006-11
Type Journal Article
URL http://hdl.handle.net/2298/10010
Right ? 2006 Elsevier Ireland Ltd and the Japan
Neuroscience Society All rights reserved.
Receiving Editor: Dr. Seiji Ozawa 
 
 
Contribution of endogenous glycine site NMDA agonists to excitotoxic retinal 
damage in vivo 
 
Yasuhiro Hamaa, Hiroshi Katsukia, Yoshinaga Tochikawab, Chihiro Suminakaa, Toshiaki 
Kumea, Akinori Akaikea
 
aDepartment of Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto 
University, 46-29 Yoshida-shimoadachi-cho, Sakyo-ku, Kyoto 606-8501, Japan 
bInstitute of Research and Development, Fujimoto Pharmaceutical Corporation, 1-3-40 
Nishiotsuka, Matsubara-shi, Osaka 580-8503, Japan 
 
 
 
Address correspondence to: Akinori Akaike, Ph.D. 
Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University 
46-29 Yoshida-shimoadachi-cho, Sakyo-ku, Kyoto 606-8501, Japan 
Phone: +81-75-753-4550, Fax: +81-75-753-4579 
E-mail: aakaike@pharm.kyoto-u.ac.jp
 
 
Number of Pages, 21; Number of Figures, 5; Number of Tables, 0 
1 
Abstract 
N-methyl-D-aspartate (NMDA) receptors, which play an important role in neuronal 
excitotoxicity, require not only agonists at the glutamate-binding site but also co-agonists at 
the glycine site for their activation.  Here we examined the role of endogenous agonists at 
the glycine site of NMDA receptors in excitotoxic retinal damage in vivo.  To quantify the 
number of surviving retinal ganglion cells (RGCs), we injected a retrograde tracer, 
fluoro-gold, into the superior colliculus bilaterally and subsequently counted RGCs on 
whole-mounted retinas.  Co-injection of 5’7-dichlorokynurenic acid (300 nmol), a 
competitive antagonist at the glycine site of NMDA receptors, rescued RGCs from damage 
induced by 200 nmol NMDA.  On the other hand, RGC death induced by 20 nmol NMDA 
was enhanced by addition of glycine (10 nmol), D-serine (10 nmol) or a competitive glycine 
transporter-1 inhibitor, sarcosine (0.3 or 3 nmol).  Moreover, application of 
D-serine-degrading enzyme, D-amino acid oxidase (30 mU), partially suppressed RGC death 
induced by 20 nmol NMDA.  These results suggest that the severity of excitotoxic retinal 
damage in vivo depends on the levels of both glycine and D-serine. 
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1. Introduction 
Glutamate is the major excitatory neurotransmitter in the retina and elsewhere in the 
central nervous system (CNS) (Kemp et al., 2002; Yang, 2004).  Retinal bipolar cells send 
excitatory glutamatergic inputs to retinal ganglion cells (RGCs), which in turn transmit visual 
information to the brain via their axons that comprise the optic nerve.  RGCs express distinct 
subclasses of glutamate receptors such as ionotropic N-methyl-D-aspartate (NMDA) and 
non-NMDA receptors as well as metabotropic glutamate receptors (Yang, 2004).  On the 
other hand, many lines of evidence suggest that pathological conditions in the retina including 
glaucoma (Nucci et al, 2005; Guo et al., 2006), ischemia (Adachi et al., 1998; Osborne et al., 
1999) and optic neuropathy (Levkovitch-Verbin et al., 2003) are associated with dysregulation 
of glutamatergic system.  Particularly, NMDA subtype of glutamate receptors is thought to 
play a principal role in neuronal degeneration in the retina, owing to its high Ca2+ 
permeability (Adachi et al., 1998; Lam et al., 1999).  In an experimental rat glaucoma model, 
expression levels of glutamate transporters are decreased, which may result in elevation of 
extracellular glutamate concentration and over-activation of glutamate receptors (Martin et al. 
2002; but see Hartwick et al., 2005). 
Activation of NMDA receptor channels is well known to require a co-agonist at the 
glycine site, in addition to glutamate (Schell, 2004).  At present, potential candidates for 
endogenous glycine site agonists in the retina are glycine and D-serine.  Glycine is used as an 
inhibitory neurotransmitter by subpopulation of amacrine cells in the retina (Menger et al., 
1998), but might also be supplied to the retinal tissue via peripheral circulation (Pow, 1998).  
More recently, the presence of another glycine site agonist D-serine as well as its synthesizing 
enzyme serine racemase has been proven in retinal astrocytes and Müller cells (Stevens et al., 
2003).  Several reports have clearly demonstrated that glycine and/or D-serine contribute to 
physiological activation of NMDA receptors in RGCs (Lukasiewicz and Roeder, 1995; 
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Stevens et al., 2003). 
On the basis of their critical requirement for NMDA receptor activation, endogenous 
glycine site agonists may also play an important role under retinal pathological conditions 
involving excitotoxic events.  In the brain, several studies demonstrated remarkable 
protective effects of glycine site antagonists against NMDA receptor-mediated neuronal injury 
(Foster et al., 1990; Patel et al., 1990).  Recently, we and others have reported that 
endogenous D-serine contributes to NMDA-induced neuronal damage in cerebrcortical slices 
(Katsuki et al., 2004) and cultured hippocampal slices (Shleper et al., 2005).  Here, we 
addressed whether endogenous glycine, D-serine, or both, regulate excitotoxic damage of 
RGCs in vivo, using a retinal degeneration model produced by intravitreal injection of 
NMDA. 
 
 
2. Materials and methods 
2.1. Drugs 
We dissolved 5,7-dichlorokynurenic acid (DCKA; Tocris Cookson Inc., Bristol, UK) 
in 50% sodium hydroxide for intravitreal injection.  The following drugs were dissolved in 
0.1 M sterile phosphate buffer (pH 7.4) for intravitreal injection; NMDA (Sigma-Aldrich, St. 
Louis, MO), MK-801 (Sigma-Aldrich), glycine (Nacalai Tesque, Kyoto, Japan), D-serine 
(Nacalai Tesque), sarcosine (Nacalai Tesque) and D-amino acid oxidase (DAAOX; MP 
Biomedicals, Irvine, CA). 
 
2.2. Intravitreal injection of drugs 
Experiments were performed on male Sprague-Dawley rats (7 week old; Nihon SLC, 
Shizuoka, Japan).  Animals were housed at 21 - 23 °C on a 12-h light-dark cycle (lights on at 
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8:00 AM).  Food and water were freely available.  All animal procedures were approved by 
our institutional animal experimentation committee and were in accordance with the ARVO 
Statement for the Use of Animals in Ophthalmic and Vision Research.  Each rat was 
anesthetized with an intraperitoneal injection of sodium pentobarbital (50 - 70 mg/kg).  We 
carried out intravitreal injection using a 33-gauge needle connected to a Teflon tube with a 
25-μL Hamilton syringe after dilation of the rat pupil with 1% atropine sulfate.  The tip of 
the needle was inserted through the dorsal limbus of the eye.  We injected 5 μL of a drug 
solution slowly over a period of 1 min (Adachi et al., 1998; Takahata et al., 2003). 
 
2.3. Analysis for retinal ganglion cell loss 
We labeled surviving RGCs in a retrograde manner, essentially according to the 
methods described previously (Takahata et al., 2003).  Three days after intravitreal injection 
of drugs, each rat was anesthetized by an intraperitoneal injection of sodium pentobarbital (50 
- 70 mg/kg), and the head was placed firmly in a stereotaxic apparatus.  We injected 2.5 μL 
of a solution of 4% fluoro-gold (FG; Fluorochrome, LLC, Colorado, USA) bilaterally into the 
superior colliculus (−6.3 mm posterior to bregma, ±1.5 mm lateral to the midline, −3.6 mm 
from the surface of the skull). 
Four days after FG injection (e.g., seven days after intravitreal injection of drugs), 
the rat was euthanized, and both eyes were enucleated.  The eyes were fixed for 45 min in 
4% paraformaldehyde in phosphate-buffered saline (pH 7.4).  The retinas were dissected as 
flattened whole mounts with four radial cuts, mounted with vitreal side up on slides and 
covered with Gel/Mount (Biomeda Corp., Foster City, CA, USA). 
To count FG-labeled RGCs, we randomly selected four fields of 230 × 310 μm2 from 
the central area (approximately 1 mm from the optic disc) and the peripheral area (more than 
3 mm from the optic disc) for each retina.  FG-labeled RGCs were counted with the aid of 
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image analysis software (Scion Image).  For each animal, the mean value for the right eye 
was expressed as a ratio (%) to that for the intact left eye.  Data are expressed as mean ± 
SEM.  Statistical analyses were performed with one-way analysis of variance followed by 
Student-Newman-Keuls’ test, and differences were considered significant at P < 0.05. 
Although sampling methods for cell counting, using retinal cross sections or a 
fractional area of retinal flat mounts like in the present study, have been used widely (Huang 
et al., 2005; Manabe et al., 2005), several problems associated with these methods have been 
claimed by Danias et al. (2002, 2006).  The degree of RGC damage is highly variable in the 
case of the vein cauterization model of glaucoma in the rat (Danias et al., 2006), which 
necessitates a large scale of cell counting to draw statistically significant results.  On the 
other hand, we observed during inspection of retinal whole mounts that NMDA cytotoxicity 
and the effects of drugs described below were consistent between different animals, and radial 
asymmetry of drug effects was not apparent within a given retina.  Therefore, the method of 
cell counting should not produce a bias that may affect the conclusion of the present study. 
 
2.4. Histological analysis 
In several sets of experiments, we examined histological alterations in retinal tissues 
by conventional hematoxylin/eosin staining (Takahata et al., 2003).  Seven days after 
intravitreal injection of drugs, each rat was euthanized and both eyes were enucleated.  We 
fixed the eyes in phosphate-buffered 4% formalin and 1% glutaraldehyde aqueous solution 
(pH 7.4), and then in phosphate-buffered 10% formalin solution (pH 7.4).  After fixation, the 
eyes were embedded in paraffin and cut into 5-μm-thick sections through the optic disc of 
each eye.  The sections were then stained with hematoxylin and eosin (HE).  We took 
photomicrographs of each section within 1 mm of the optic disk. 
Occurrence of DNA fragmentation was examined by terminal deoxynucleotidyl 
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transferase-mediated dUTP nick end-labeling (TUNEL).  At 18 h after intravitreal drug 
injection, each rat was euthanized and both eyes were enucleated.  After fixation, the eyes 
were embedded in paraffin and cut into horizontal 5-μm-thick sections through the optic disc 
of each eye.  We applied In situ Apoptosis Detection Kit (Takara Bio Inc., Shiga, Japan) to 
paraffin sections, according to the manufacturer’s protocol with slight modification.  Briefly, 
FITC-dUTP was catalytically added by TdT to the 3’-OH ends of double- or single-stranded 
DNA.  The sections were then incubated with Anti-FITC HRP conjugate at 37°C overnight.  
Following these processes, the sections were incubated with anti-rabbit IgG (Vector, 
Burlingame, CA) and then with ABC solution (ABC Elite Kit; Vector) at room temperature, 
respectively for 2 h.  We visualized the labeled product with diaminobenzidine that yielded 
brown granules localized to apoptotic cells.  Finally, we counterstained the sections with 1% 
methyl green.  Omission of TdT gave completely negative results. 
 
 
3. Results 
3.1. Effect of glycine site blockade on NMDA-induced retinal damage 
As previously described (Takahata et al., 2003), intravitreal injection of 200 nmol 
NMDA caused a prominent decrease in the number of FG-labeled RGCs assessed at 7 days 
after injection (Fig. 1A).  The degree of the decrease was comparable between the central 
area and the peripheral area.  To ascertain whether the presence of endogenous glycine site 
agonists is critical for NMDA cytotoxicity, we examined the effect of DCKA (30 - 300 nmol) 
on retinal damage induced by 200 nmol NMDA.  DCKA is a potent antagonist acting at the 
glycine site of NMDA receptor complex (Baron et al., 1990).  DCKA at 300 nmol almost 
completely abolished NMDA-induced loss of RGCs both at the central area and the peripheral 
area (Fig. 1A and B).  The effect of lower doses of DCKA was modest, but a significant 
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effect of 30 nmol DCKA was observed at the peripheral area. 
Consistent with results on whole-mounted retina, histological analysis of transverse 
retinal sections with HE staining revealed that 200 nmol NMDA caused cell loss in the 
ganglion cell layer and also a marked reduction in the thickness of the inner plexiform layer 7 
days after injection (Fig. 2A).  Co-injection of 300 nmol DCKA with NMDA completely 
rescued cells in the ganglion cell layer and preserved the thickness of the inner plexiform 
layer.  TUNEL of transverse retinal sections revealed that positively-stained cells, which 
were not evident in vehicle-treated retinas, were distributed in the ganglion cell layer (GCL) 
at 18 h after intravitreal injection of 200 nmol NMDA (Fig. 2B).  At this time point, cell loss 
in GCL and decrease in the thickness of the inner plexiform layer were not prominent, 
indicating that apoptotic processes precede NMDA-induced degeneration of RGCs.  
Co-injection of 300 nmol DCKA with NMDA eliminated the appearance of TUNEL-positive 
cells in GCL (Fig. 2B).  We also noted appearance of many TUNEL-positive cells in the 
inner nuclear layer (INL), which was also eliminated by DCKA.  This is consistent with the 
fact that amacrine cells located in this layer are vulnerable to NMDA cytotoxicity (Lam et al., 
1999).  The apparently large number of TUNEL-positive cells in INL is likely to reflect a 
much larger number of cells in this layer than in GCL, and the percentage of cell loss in INL 
seemed to be very low (Fig. 2A).  We did not perform further examinations on INL, because 
dense package of cells in this layer hindered accurate assessment of the number of surviving 
cells. 
 
3.2. Effects of glycine site agonists on NMDA-induced RGC death 
Several lines of evidence suggest that the glycine site of NMDA receptors is not 
saturated in the CNS, including the retina (Chen et al., 2003; Hashimoto et al., 1992; Stevens 
et al., 2003).  To address this possibility, we examined whether exogenous application of 
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glycine site agonists could influence the degree of NMDA cytotoxicity.  As shown in Fig. 3A, 
co-injection of 10 nmol glycine significantly exacerbated RGC death induced by 20 nmol 
NMDA at the peripheral area.  Glycine also tended to exacerbate RGC death at the central 
area, although the effect did not reach statistical significance.  On the other hand, 
co-injection of 10 nmol D-serine significantly exacerbated RGC death by 20 nmol NMDA at 
both the central and the peripheral areas (Fig. 3B).  However, neither glycine nor D-serine 
influenced excitotoxic consequences induced by 200 nmol NMDA.  Neither glycine nor 
D-serine alone affected the viability of RGCs. 
 
3.3. Effect of a glycine transporter-1 inhibitor on NMDA-induced RGC death 
Na+/Cl−-dependent, high-capacity glycine transporters (GLYTs) have been reported 
to regulate extracellular glycine concentrations efficiently in the forebrain (Chen et al., 2003).  
Two subtypes of GLYTs encoded by different genes, GlyT1 and GlyT2, are differentially 
expressed in the CNS (Zafra et al., 1995).  In the retina, distribution of GLYT1 matches that 
of glycine-immunoreactive amacrine cells, whereas GLYT2 is absent from the retina (Zafra et 
al., 1995; Menger et al., 1998).  Thus, we examined the effect of sarcosine, a competitive 
inhibitor of GLYT1 (Guastella et al., 1992), on NMDA-induced RGC death.  Co-injection of 
0.3 or 3 nmol sarcosine and 20 nmol NMDA 1 day after injection of the same doses of 
sarcosine induced more severe RGC death than injection of 20 nmol NMDA alone 1 day after 
vehicle injection (Fig. 4).  The exacerbating effect of sarcosine on RGC death was 
significant only at the central area of the retina, although tendency for exacerbation was 
observed also at the peripheral area. 
 
3.4. Effect of D-serine-degrading enzyme on NMDA-induced RGC death 
In the final set of experiments, we examined the effect of DAAOX on 
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NMDA-induced RGC death, to verify whether D-serine engages in excitotoxicity as an 
endogenous glycine site agonist in the retina.  DAAOX is an enzyme that catalyzes oxidative 
deamination of D-amino acids (D’Aniello et al., 1993; Denu and Fitzpatrick, 1994).  At 
physiological pH, this enzyme is highly selective for D-serine and does not act on other amino 
acids, including glycine.  We intravitreally injected DAAOX and 20 nmol NMDA 1 day 
after injection of the same dose of DAAOX.  The results presented in Fig. 5 show that 30 
mU DAAOX significantly reduced RGC death induced by NMDA at the peripheral area of 
the retina.  The protective effect of DAAOX was not prominent at the central area. 
 
 
4. Discussion 
In the present study, we aimed at uncovering the characteristics of retinal 
excitotoxicity by focusing on the glycine site of NMDA receptors.  First of all, we examined 
the effect of DCKA, a potent competitive antagonist at the glycine site (Baron et al. 1990).  
DCKA at a sufficient dose applied with NMDA almost completely blocked loss of RGCs, 
thinning of the inner plexiform layer, and occurrence of DNA fragmentation revealed by 
TUNEL.  These results clearly indicate that glycine site stimulation by endogenous ligands 
is obligatory for NMDA-induced retinal damage.  The effects of DCKA observed in this 
study are not surprising, given the fact that a glycine site ligand is essential for activation of 
NMDA receptors (Schell, 2004).  To our knowledge, however, protective effect of glycine 
site antagonists against NMDA-induced retinal damage in vivo has not been investigated 
directly.  The only relevant report is that systemic administration of kynurenine, a precursor 
of a glycine site antagonist kynurenic acid, attenuates NMDA cytotoxicity in rat retina 
(Vorwerk et al., 1996). 
The second question we addressed was whether endogenous glycine site ligands are 
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present extracellularly in the retina at levels sufficient for full activation of NMDA receptors.  
Results of co-injection experiments showed that D-serine and glycine exacerbated RGC death 
induced by 20 nmol NMDA.  These results suggest that the glycine site of NMDA receptors 
on RGCs in vivo is not normally saturated, and that changes in the extracellular levels of 
glycine site ligands can influence the degree of excitotoxic damage.  Unsaturated properties 
of the NMDA receptor glycine site have been suggested in isolated retinal tissues (Stevens et 
al., 2003), but endogenous ligands might have been partially wiped out by external perfusion 
in in vitro preparations. 
D-Serine significantly exacerbated NMDA cytotoxicity both at the central area and at 
the peripheral area of the retina, whereas glycine showed a significant effect only at the 
peripheral area.  This difference may be attributable to the fact that glycine is a weaker 
agonist than D-serine at the NMDA receptor glycine site (Matsui et al., 1995).  Another 
interpretation is a potential difference in the distribution of uptake systems of glycine and 
D-serine.  Different types of transporters participate in clearance of extracellular glycine and 
D-serine.  That is, a glycine transporter GLYT1 expressed on retinal amacrine cells (Zafra et 
al., 1995; Menger et al., 1998) plays an important role in regulation of synaptic glycine 
concentration (Chen et al., 2003) and glycine content in retinal neurons (Pow, 1998).  
NMDA receptor-mediated transmission is augmented in hippocampal CA1 synapses in 
heterozygous GLYT1 knockout mice (Tsai et al., 2004; Gabernet et al., 2005), indicating that 
GLYT1 maintains extracellular glycine concentration below the levels saturating NMDA 
receptor glycine site.  On the other hand, uptake of extracellular D-serine in the retina is 
probably accomplished by ASCT-like neutral amino acid transporters (O’Brien et al., 2005).  
Therefore, the effects of exogenously applied glycine site agonists may well be influenced by 
activities of these transporters.  Unfortunately, however, there is no information available 
whether or not the expression levels or activities of these transport systems exhibit any 
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regional differences within the retinal tissues. 
In contrast to that induced by 20 nmol NMDA, RGC death induced by a higher dose 
(200 nmol) of NMDA was not exacerbated by glycine and D-serine.  Reasons for this 
insensitivity are unclear, but a possible explanation is that a subpopulation of RGCs is 
resistant to NMDA cytotoxicity (Dreyer et al., 1994).  Thus, a high dose of NMDA is 
sufficient to damage almost all NMDA-sensitive RGCs even in the presence of only modest 
levels of endogenous glycine site agonists.  In this case, supplementation of glycine site 
agonists may no longer increase the number of damaged RGCs, because the remaining 
population of RGCs is relatively NMDA-resistant. 
Effects of sarcosine and DAAOX on NMDA-induced RGC death provide further 
evidence for important roles of endogenous glycine site agonists.  Sarcosine, a competitive 
inhibitor of GLYT1, exacerbated RGC death induced by 20 nmol NMDA, indicating that 
regulation of extracellular glycine levels by GLYT1 limits over-activation of NMDA receptors 
leading to retinal damage.  Interestingly, the effect of sarcosine was more prominent in the 
central area than in the peripheral area.  Combined with differential effects of exogenous 
glycine on NMDA cytotoxicity between different areas (Fig. 3A), these results imply that 
glycine transport activity exerts more profound influences on regulation of extracellular 
glycine in the central area than in the peripheral area of the retina. 
In contrast to the effect of sarcosine, the effect of DAAOX on NMDA-induced 
retinal damage was significant only in the peripheral area.  These results offer an interesting 
possibility that different kinds of endogenous glycine site agonists play a dominant role in the 
central and the peripheral area of the retina: that is, glycine dominates in the central area 
whereas D-serine dominates in the peripheral area.  Again, however, no information is 
available concerning regional distribution of D-serine and serine racemase, the D-serine 
synthesizing enzyme, within the retinal tissues.  In any case, the present results demonstrated 
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for the first time that endogenous D-serine is at least in part involved in pathological processes 
mediated by NMDA receptor over-activation in the retina.  To our knowledge, the present 
study is also the first one suggesting that D-serine plays an active role in excitotoxicity in vivo. 
Glial cells are emerging as important participants in various neurodegenerative 
conditions including excitotoxic injury (Kim and de Vellis, 2005; Seifert et al., 2006).  With 
regard to glycine site ligands, Müller cells and astrocytes in the retina are potential sources of 
D-serine (Stevens et al., 2003).  Moreover, glial cell activation is associated with glaucoma 
(Wang et al., 2000), and activated microglia may serve as an additional source of D-serine 
(Wu and Berger, 2004).  Thus, states of glial cells (quiescent or activated) may be taken into 
consideration to understand the roles of endogenous glycine site ligands under pathological 
conditions. 
Overall, the levels of endogenous glycine site agonists influence the severity of 
NMDA receptor-mediated excitotoxic retinal damage in vivo.  Both glycine and D-serine 
contribute to the excitotoxic processes in the retina, but their relative contribution may not be 
uniform throughout the retinal tissue.  Further studies are required concerning distribution 
and activities of key molecules involved in the synthesis, release and uptake of glycine and 
D-serine within the retina.  These kinds of information should provide useful insights into the 
regulatory mechanisms of excitotoxicity, which are relevant to the pathogenesis of various 
retinal neurodegenerative disorders.  Finally, we must note that findings in the present study 
rely solely on morphological analysis.  Whether manipulation of the extent of glycine site 
stimulation under pathological conditions leads to preservation of retinal functions, e.g., as 
reflected by electroretinograms, remains an important issue to be determined. 
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Figure legends 
Fig. 1.  Effect of a glycine site antagonist on NMDA-induced retinal damage.  A, 
Representative photomicrographs of the central area of whole-mounted preparations of retinas 
that received intravitreal injection of vehicle, 200 nmol NMDA, or 200 nmol NMDA plus 10 
nmol DCKA.  Scale bar, 50 μm.  B, Summary of the effect of DCKA on NMDA-induced 
loss of RGCs at the central and the peripheral areas 7 days after intravitreal injection.  Means 
of the number of FG-labeled surviving RGCs for the right eye of each animal were 
normalized to those for the left (intact) eye and are shown as percentages.  *** P < 0.001 vs. 
vehicle.  # P < 0.05, ### P < 0.001.  n = 9 - 11. 
 
Fig. 2.  Representative photomicrographs of hematoxylin-eosin (HE) -stained (A) and 
TUNEL-stained (B) retinal sections from eyes that received intravitreal injection of vehicle 
(left), 200 nmol NMDA (center) or 200 nmol NMDA plus 300 nmol DCKA (right).  Eyes 
were enucleated at 18 h or 7 days after injection, and then TUNEL staining or HE staining 
was performed respectively.  GCL, ganglion cell layer; IPL, inner plexiform layer; INL, 
inner nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear layer.  Scale bar, 20 μm. 
 
Fig. 3.  Effects of glycine site agonists on NMDA-induced RGC death 7 days after 
intravitreal injection.  Effect of glycine (10 nmol; A) and D-serine (10 nmol; B) at the central 
and the peripheral areas are shown.  Glycine site agonists were simultaneously applied with 
NMDA at indicated doses (in nmol).  Means of the number of FG-labeled surviving RGCs 
for the right eye of each animal were normalized to those for the left (intact) eye and are 
shown as percentages.  * P < 0.05, *** P < 0.001 vs. vehicle.  # P < 0.05, ### P < 0.001.  
n = 5 - 8. 
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Fig. 4.  Effect of a glycine transporter inhibitor on NMDA-induced RGC death 7 days after 
intravitreal injection.  Sarcosine at indicated doses was injected intravitreally, and 24 h later, 
it was again injected simultaneously with 20 nmol NMDA.  Means of the number of 
FG-labeled surviving RGCs for the right eye of each animal were normalized to those for the 
left (intact) eye and are shown as percentages.   *** P < 0.001 vs. vehicle.  # P < 0.05.  n 
= 6 - 9. 
 
Fig. 5.  Effects of a D-serine degrading enzyme on NMDA-induced RGC death 7 days after 
intravitreal injection.  DAAOX at indicated doses was injected intravitreally, and 24 h later, 
it was again injected simultaneously with 20 nmol NMDA.  Means of the number of 
FG-labeled surviving RGCs for the right eye of each animal were normalized to those for the 
left (intact) eye and are shown as percentages.   ** P < 0.01, *** P < 0.001 vs. vehicle.  # 
P < 0.05.  n = 4 - 8. 
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